Changes in symptom severity in Taiwanese lung cancer patients after gefitinib treatment: A pilot study

Shu Yi Wang, Chun Ming Tsai, Chia-Chin Lin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: The purpose of this study was to investigate symptom severity in advanced non-small cell lung cancer patients prior to gefitinib treatment and at 1-, 3- and 6-month intervals after starting treatment. Methodology: Fifty seven patients completed the Taiwanese version of the M.D. Anderson Symptom Inventory. The data were analysed using descriptive statistics, the Friedman non-parametric test, and Pearson correlation coefficients. Results: Symptoms of nausea, difficulty remembering, lack of appetite, sadness, and vomiting increased at 1 month after treatment started, pain and shortness of breath increased at 3 months, and disturbed sleep, drowsiness, and numbness increased after 6 months. Fatigue and dry mouth increased at 3 months after treatment started and then decreased. Only distress decreased throughout the course of treatment. Conclusion: The findings may lead to the development of better clinical guidelines and improved information for patients on when to expect the greatest impact from their symptoms during the course of treatment.

Original languageEnglish
Pages (from-to)135-142
Number of pages8
JournalInternational Journal of Palliative Nursing
Volume20
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Lung Neoplasms
Therapeutics
Hypesthesia
Sleep Stages
Appetite
Nonparametric Statistics
Non-Small Cell Lung Carcinoma
Dyspnea
Nausea
Vomiting
Fatigue
Mouth
gefitinib
Sleep
Guidelines
Pain
Equipment and Supplies

Keywords

  • Gefitinib treatment
  • Non-small cell lung cancer
  • Symptom interference
  • Symptom severity
  • Targeted therap

ASJC Scopus subject areas

  • Advanced and Specialised Nursing

Cite this

Changes in symptom severity in Taiwanese lung cancer patients after gefitinib treatment : A pilot study. / Wang, Shu Yi; Tsai, Chun Ming; Lin, Chia-Chin.

In: International Journal of Palliative Nursing, Vol. 20, No. 3, 2014, p. 135-142.

Research output: Contribution to journalArticle

@article{ed9b95406c60457ea16cabbbd5f77f4f,
title = "Changes in symptom severity in Taiwanese lung cancer patients after gefitinib treatment: A pilot study",
abstract = "Aim: The purpose of this study was to investigate symptom severity in advanced non-small cell lung cancer patients prior to gefitinib treatment and at 1-, 3- and 6-month intervals after starting treatment. Methodology: Fifty seven patients completed the Taiwanese version of the M.D. Anderson Symptom Inventory. The data were analysed using descriptive statistics, the Friedman non-parametric test, and Pearson correlation coefficients. Results: Symptoms of nausea, difficulty remembering, lack of appetite, sadness, and vomiting increased at 1 month after treatment started, pain and shortness of breath increased at 3 months, and disturbed sleep, drowsiness, and numbness increased after 6 months. Fatigue and dry mouth increased at 3 months after treatment started and then decreased. Only distress decreased throughout the course of treatment. Conclusion: The findings may lead to the development of better clinical guidelines and improved information for patients on when to expect the greatest impact from their symptoms during the course of treatment.",
keywords = "Gefitinib treatment, Non-small cell lung cancer, Symptom interference, Symptom severity, Targeted therap",
author = "Wang, {Shu Yi} and Tsai, {Chun Ming} and Chia-Chin Lin",
year = "2014",
doi = "10.12968/ijpn.2014.20.3.135",
language = "English",
volume = "20",
pages = "135--142",
journal = "International Journal of Palliative Nursing",
issn = "1357-6321",
publisher = "MA Healthcare Ltd",
number = "3",

}

TY - JOUR

T1 - Changes in symptom severity in Taiwanese lung cancer patients after gefitinib treatment

T2 - A pilot study

AU - Wang, Shu Yi

AU - Tsai, Chun Ming

AU - Lin, Chia-Chin

PY - 2014

Y1 - 2014

N2 - Aim: The purpose of this study was to investigate symptom severity in advanced non-small cell lung cancer patients prior to gefitinib treatment and at 1-, 3- and 6-month intervals after starting treatment. Methodology: Fifty seven patients completed the Taiwanese version of the M.D. Anderson Symptom Inventory. The data were analysed using descriptive statistics, the Friedman non-parametric test, and Pearson correlation coefficients. Results: Symptoms of nausea, difficulty remembering, lack of appetite, sadness, and vomiting increased at 1 month after treatment started, pain and shortness of breath increased at 3 months, and disturbed sleep, drowsiness, and numbness increased after 6 months. Fatigue and dry mouth increased at 3 months after treatment started and then decreased. Only distress decreased throughout the course of treatment. Conclusion: The findings may lead to the development of better clinical guidelines and improved information for patients on when to expect the greatest impact from their symptoms during the course of treatment.

AB - Aim: The purpose of this study was to investigate symptom severity in advanced non-small cell lung cancer patients prior to gefitinib treatment and at 1-, 3- and 6-month intervals after starting treatment. Methodology: Fifty seven patients completed the Taiwanese version of the M.D. Anderson Symptom Inventory. The data were analysed using descriptive statistics, the Friedman non-parametric test, and Pearson correlation coefficients. Results: Symptoms of nausea, difficulty remembering, lack of appetite, sadness, and vomiting increased at 1 month after treatment started, pain and shortness of breath increased at 3 months, and disturbed sleep, drowsiness, and numbness increased after 6 months. Fatigue and dry mouth increased at 3 months after treatment started and then decreased. Only distress decreased throughout the course of treatment. Conclusion: The findings may lead to the development of better clinical guidelines and improved information for patients on when to expect the greatest impact from their symptoms during the course of treatment.

KW - Gefitinib treatment

KW - Non-small cell lung cancer

KW - Symptom interference

KW - Symptom severity

KW - Targeted therap

UR - http://www.scopus.com/inward/record.url?scp=84901920694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901920694&partnerID=8YFLogxK

U2 - 10.12968/ijpn.2014.20.3.135

DO - 10.12968/ijpn.2014.20.3.135

M3 - Article

C2 - 24675540

AN - SCOPUS:84901920694

VL - 20

SP - 135

EP - 142

JO - International Journal of Palliative Nursing

JF - International Journal of Palliative Nursing

SN - 1357-6321

IS - 3

ER -